In this analysis, a further censoring criterion was applied so that patients were censored from follow-up on the date of switch to, or add on of, the other study drug (ie, follow-up among patients treated with DPP4 inhibitors was censored on the date of a GLP1 receptor agonist prescription, and vice versa)
The non-overlap is the key
They are self-reported marketing claims, not independently verified clinical outcomes
(2024, April 20)
I have been taking Pendulum Metabolic Daily, which has beneficial strands not found anywhere else
Others Key Target Audience Market Players Investors End-users Government Authorities Consulting and Research Firm Venture capitalists Value-Added Resellers (VARs) Market Segment This study forecasts revenue at Germany, regional, and country levels from 2020 to 2035